Congress' Delay May Hurt Drugmakers (The Motley Fool)
The reauthorization of the Prescription Drug User Fee Act is delayed.

Santarus Receives Notice of Paragraph IV Certification Against Patents for ZEGERID Capsules (Finanzen.net)
Santarus, Inc. (Nasdaq: SNTS), a specialty pharmaceutical company, today announced that it and its licensor, the University of Missouri, have received a Paragraph IV Certification Notice from Par Pharmaceutical, Inc. advising of the ...